Nuclear factor-κB dimer exchange promotes a p21waf1/cip1 superinduction response in human T leukemic cells

Molecular Cancer Research

Volumn 4, Issue 2, 2006, Pages 101-112

  Chang, Pei Yun ^a   Miyamoto, Shigeki ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P105; PROTEIN P50; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA; DNA BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA;

ARTICLE; CELL LINE; HUMAN; IMMUNOPRECIPITATION; LEUKEMIA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL CULTURE; CELL CYCLE; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; DIMERIZATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; T CELL LEUKEMIA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL CYCLE; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIMERIZATION; DNA; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ETOPOSIDE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPRECIPITATION; LEUKEMIA, T-CELL; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 33645130336     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0259     Document Type: Article

References (90)

1. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev 1995;9:2723-35.
2. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
3. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNF-α-induced apoptosis. Genes Dev 1999;13:382-7.
4. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
5. Tang G, Minemoto Y, Dibling B, et al. Inhibition of JNK activation through NF-κB target genes. Nature 2001;414:313-7.
6. Grumont RJ, Rourke IJ, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor Hgation-induced apoptosis. Genes Dev 1999;13:400-11.
7. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis C-IAP2 is under NF-κB control. Proc Natl Acad Sci U S A 1997;94:10057-62.
8. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
9. 2-M when it is transactivation defective. EMBO J 1995;14:4994-5005.
10. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV, Fontana JA. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 1994;9:3407-15.
11. waf1/cip1 induction. Mol Cancer Res 2005;3:345-53.
12. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
13. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
14. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004;18:2195-224.
15. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59.
16. Ghosh S, Gifford AM, Riviere LR, Tempst P, Nolan GP, Baltimore D. Cloning of the p50 DNA binding subunit of NF-κB: homology to rel and dorsal. Cell 1990;62:1019-29.
17. Kieran M, Blank V, Logeat F, et al. The DNA binding subunit of NFκB is identical to factor KBF1 and homologous to the rel oncogene product. Cell 1990;62:1007-18.
18. Nolan GP, Ghosh S, Liou HC, Tempst P, Baltimore D. DNA binding and IκB inhibition of the cloned p65 subunit of NF-κB, a rel-related polypeptide. Cell 1991;64:961-9.
19. Gerondakis S, Grossmann M, Nakamura Y, Pohl T, Grumont R. Genetic approaches in mice to understand Rel/NF-κB and IκB function: transgenics and knockouts. Oncogene 1999;18:6888-95.
20. Attar RM, Caamano J, Carrasco D, et al. Genetic approaches to study Rel/NF-κB/IκB function in mice. Semin Cancer Biol 1997;8:93-101.
21. Liptay S, Schmid RM, Nabel EG, Nabel GJ. Transcriptional regulation of NF-κB2: evidence for κB-mediated positive and negative autoregulation. Mol Cell Biol 1994;14:7695-703.
22. Grumont RJ, Richardson IB, Gaff C, Gerondakis S. rel/NF-κB nuclear complexes that bind kB sites in the murine c-rel promoter are required for constitutive crel transcription in B-cells. Cell Growth Differ 1993;4:731-43.
23. Bren GD, Solan NJ, Miyoshi H, Pennington KN, Pobst LJ, Paya CV. Transcription of the RelB gene is regulated by NF-κB. Oncogene 2001;20:7722-33.
24. Lombardi L, Ciana P, Cappellini C, et al. Structural and functional characterization of the promoter regions of the NFKB2 gene. Nucleic Acids Res 1995;23:2328-36.
25. Paya CV, Ten RM, Bessia C, Alcami J, Hay RT, Virelizier JL. NF-κB-dependent induction of the NF-κB p50 subunit gene promoter underlies self-perpetuation of human immunodeficiency virus transcription in monocytic cells. Proc Natl Acad Sci U S A 1992;89:7826-30.
26. Ten RM, Paya CV, Israel N, et al. The characterization of the promoter of the gene encoding the p50 subunit of NF-κB indicates that it participates in its own regulation. EMBO J 1992;11:195-203.
27. Lambert PF, Ludford-Menting MJ, Deacon NJ, Kola I, Doherty RR. The nfkb1 promoter is controlled by proteins of the Ets family. Mol Biol Cell 1997;8:313-23.
28. Miyamoto S, Schmitt MJ, Verma IM. Qualitative changes in the subunit composition of κB-binding complexes during murine B-cell differentiation. Proc Natl Acad Sci U S A 1994;91:5056-60.
29. Liou HC, Sha WC, Scott ML, Baltimore D. Sequential induction of NFκB/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994;14:5349-59.
30. Saccani S, Pantano S, Natoli G. Modulation of NF-κB activity by exchange of dimers. Mol Cell 2003;11:1563-74.
31. Dorado B, Portoles P, Ballester S. NF-κB in Th2 cells: delayed and long-lasting induction through the TCR complex. Eur J Immunol 1998;28:2234-44.
32. Banerjee D, Liou HC, Sen R. c-Rel-dependent priming of naive T cells by inflammatory cytokines. Immunity 2005;23:445-58.
33. Piret B, Piette J. Topoisomerase poisons activate the transcription factor NF-κB in ACH-2 and CEM cells. Nucleic Acids Res 1996;24:4242-8.
34. Lin SC, Wortis HH, Stavnezer J. The ability of CD40L, but not lipopolysaccharide, to initiate immunoglobulin switching to immunoglobulin GI is explained by differential induction of NF-κB/Rel proteins. Mol Cell Biol 1998;18:5523-32.
35. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002;62:1083-6.
36. Harhaj EW, Maggirwar SB, Good L, Sun SC. CD28 mediates a potent costimulatory signal for rapid degradation of IκBβ which is associated with accelerated activation of various NF-κB/Rel heterodimers. Mol Cell Biol 1996;16:6736-43.
37. Maggirwar SB, Harhaj EW, Sun SC. Regulation of the interleukin-2 CD28-responsive element by NF-ATP and various NF-κB/Rel transcription factors. Mol Cell Biol 1997;17:2605-14.
38. Kanno T, Brown K, Franzoso G, Siebenlist U. Kinetic analysis of human T-cell leukemia virus type I Tax-mediated activation of NF-κB. Mol Cell Biol 1994;14:6443-51.
39. Schafer SL, Hiscott J, Pitha PM. Differential regulation of the HIV-1 LTR by specific NF-κB subunits in HSV-1-infected cells. Virology 1996;224:214-23.
40. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, et al. NF-κB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem 2000;275:9501-9.
41. Krappmann D, Patke A, Heissmeyer V, Scheidereit C. B-cell receptor- and phorbol ester-induced NF-κB and c-Jun N-terminal kinase activation in B cells requires novel protein kinase C's. Mol Cell Biol 2001;21:6640-50.
42. Guo B, Su TT, Rawlings DJ. Protein kinase C family functions in B-cell activation. Curr Opin Immunol 2004;16:367-73.
43. Sliva D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets 2004;4:327-36.
44. Moscat J, Rennert P, Diaz-Meco MT. PKCζ at the crossroad of NF-κB and Jak1/Stat6 signaling pathways. Cell Death Differ 2005 (epub ahead of print).
45. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003;22:1313-24.
46. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998;1:661-71.
47. 529 is controlled by casein kinase II. J Biol Chem 2000;275:32592-7.
48. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W. IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 1999;274:30353-6.
49. Chen LF, Williams SA, Mu Y, et al. NF-κB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 2005;25:7966-75.
50. Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J 2002;21:6539-48.
51. Chen LF, Greene WC. Regulation of distinct biological activities of the NFκB transcription factor complex by acetylation. J Mol Med 2003;81:549-57.
52. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001;293:1653-7.
53. Greene WC, Chen LF. Regulation of NF-κB action by reversible acetylation. Novartis Found Symp 2004;259:208-17; discussion 218-25.
54. Kieman R, Bres V, Ng RW, et al. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003;278:2758-66.
55. Cogswell PC, Scheinman RI, Baldwin AS, Jr. Promoter of the human NFκB p50/p105 gene. Regulation by NF-κB subunits and by c-REL. J Immunol 1993;150:2794-804.
56. Chen FE, Huang DB, Chen YQ, Ghosh G. Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA. Nature 1998;391:410-3.
57. Kunsch C, Ruben SM, Rosen CA. Selection of optimal κB/Rel DNA-binding motifs: interaction of both subunits of NF-κB with DNA is required for transcriptional activation. Mol Cell Biol 1992;12:4412-21.
58. Huang DB, Phelps CB, Fusco AJ, Ghosh G. Crystal structure of a free κB DNA: insights into DNA recognition by transcription factor NF-κB. J Mol Biol 2005;346:147-60.
59. Tisne C, Delepierre M, Hartmann B. How NF-κB can be attracted by its cognate DNA. J Mol Biol 1999;293:139-50.
60. Jiang J, Kosman D, Ip YT, Levine M. The dorsal morphogen gradient regulates the mesoderm determinant twist in early Drosophila embryos. Genes Dev 1991;5:1881-91.
61. Falvo JV, Thanos D, Maniatis T. Reversal of intrinsic DNA bends in the IFN-β gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 1995;83:1101-11.
62. Leung TH, Hoffmann A, Baltimore D. One nucleotide in a κB site can determine cofactor specificity for NF-κB dimers. Cell 2004;118:453-64.
63. Sordet O, Bettaieb A, Bruey JM, et al. Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells. Cell Death Differ 1999;6:351-61.
64. Sordet O, Rebe C, Leroy I, et al. Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood 2001;97:3931-40.
65. Fernandez C, Ramos AM, Sancho P, Amran D, de Blas E, Aller P. 12-O-tetradecanoylphorbol-13-acetate may both potentiate and decrease the generation of apoptosis by the antileukemic agent arsenic trioxide in human promonocytic cells. Regulation by extracellular signal-regulated protein kinases and glutathione. J Biol Chem 2004;279:3877-84.
66. Ferguson PJ, Cheng YC. Transient protection of cultured human cells against antitumor agents by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1987;47:433-41.
67. Solary E, Bertrand R, Pommier Y. Apoptosis of human leukemic HL-60 cells induced to differentiate by phorbol ester treatment. Leukemia 1994;8:792-7.
68. Sacchi N, Fiorini G, Plevani P, Badaracco G, Breviario D, Ginelli E. Acquisition of deoxyguanosine resistance by TPA-induced T lymphoid lines. J Immunol 1983;130:1622-6.
69. Hass R, Brach M, Gunji H, Kharbanda S, Kufe D. Inhibition of EGR-1 and NFκB gene expression by dexamethasone during phorbol ester-induced human monocytic differentiation. Biochem Pharmacol 1992;44:1569-76.
70. Kurata S, Matsumoto M, Nakajima H. Transcriptional control of the heme oxygenase gene in mouse M1 cells during their TPA-induced differentiation into macrophages. J Cell Biochem 1996;62:314-24.
71. 3 stimulates phosphorylation of IκBκ and synergizes with TPA to induce nuclear translocation of NFκB during monocytic differentiation of NB4 leukemia cells. Exp Cell Res 2002;272:176-84.
72. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev 2000;14:1584-8.
73. Pennington KN, Taylor JA, Bren GD, Paya CV. IκB kinase-dependent chronic activation of NF-κB is necessary for p21(WAF1/Cip1) inhibition of differentiation-induced apoptosis of monocytes. Mol Cell Biol 2001;21:1930-41.
74. CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 2003;22:351-60.
75. Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002;419:729-34.
76. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005;6:1054-60.
77. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990;10:5502-9.
78. Mayo MW, Wang CY, Cogswell PC, et al. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997;278:1812-5.
79. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-κB in p53-mediated programmed cell death. Nature 2000;404:892-7.
80. Webster GA, Perkins ND. Transcriptional cross talk between NF-κB and p53. Mol Cell Biol 1999;19:3485-95.
81. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NFκB activation: a role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 2002;1:493-503.
82. Shaffer AL, Rosenwald A, Hurt EM, et al. Signatures of the immune response. Immunity 2001;15:375-85.
83. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
84. Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL. NFKB1 is dispensable for Myc-induced lymphomagenesis. Oncogene 2005;24:6231-40.
85. Li Z, Wang X, Yu RY, et al. BCL-6 negatively regulates expression of the NF-κB1 p105/p50 subunit. J Immunol 2005;174:205-14.
86. Otsuki T, Yano T, Clark HM, et al. Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences. Blood 1995;85:2877-84.
87. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002;1:75-87.
88. Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol 2003;40:274-80.
89. Ferrando AA, Herblot S, Palomero T, et al. Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood 2004;103:1909-11.
90. O'Connor S, Shumway SD, Amanna IJ, Hayes CE, Miyamoto S. Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IκBα degradation in B cells. Mol Cell Biol 2004;24:4895-908.